The molecule that changed body composition forever. GLP-1 receptor agonist with clinically demonstrated effects on weight, appetite, and metabolic health. Now accessible in India through arq.
Semaglutide is a once-weekly GLP-1 receptor agonist that mimics the incretin hormone released naturally after meals. It acts on multiple sites in the body—the gut, brain, and pancreas—to reduce appetite, slow gastric emptying, and improve glucose metabolism. The result is sustained weight loss without caloric restriction.
Semaglutide has been rigorously studied in large-scale randomized controlled trials. The STEP program (FDA-approved 2021 for chronic weight management) demonstrated sustained, clinically significant weight loss with minimal complications in real-world patient populations.
Book a consultation with a licensed physician to discuss whether semaglutide is appropriate for your health goals and metabolic profile.